reports
EQS-News: Evotec SE stellt Ergebnisse für das Geschäftsjahr 2023 vor u...
EQS-News: Evotec SE / Schlagwort(e): Jahresergebnis Evotec SE stellt Ergebnisse für das Geschäftsjahr 2023 vor und richtet Priorität auf profitables Wachstum aus 24.04.2024 / 07:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. FINANZERGEBNIS 2023 ERREICHT IN ALLEN PUNKTEN DIE AKTUALISIERTE PROGNOSE NEUAUSRICHTUNG DER PRIORITÄT AUF PROFITABLES WACHSTUM: ANPASSUNGEN BEI GRÖẞE UND STANDORTEN, UM JÄHRLICHEN EBITDA-BEITRAG VON MEHR ALS 40 MIO. € ZU ERREICHEN EVOTECS BERICHTSSTRUKTUR VERÄNDERT SICH MIT DEM ERSTEN QUARTAL 2024 ZU DEN SEG...
EQS-News: SURTECO GROUP SE: Good start to the business year 2024 after...
EQS-News: SURTECO GROUP SE / Key word(s): Annual Report SURTECO GROUP SE: Good start to the business year 2024 after a difficult year in 2023 24.04.2024 / 07:05 CET/CEST The issuer is solely responsible for the content of this announcement. SURTECO GROUP SE: Good start to the business year 2024 after a difficult year in 2023 Earnings per share in 2023 amount to € -0.79 after € 1.63 in the previous year Sales for 2024 are projected to be in the range € 860 to 910 million. Adjusted EBITDA is expected between € 85 and 105 million. Good start to the business year 2024 wit...
EQS-News: SURTECO GROUP SE: Guter Start in das Geschäftsjahr 2024 nach...
EQS-News: SURTECO GROUP SE / Schlagwort(e): Jahresbericht SURTECO GROUP SE: Guter Start in das Geschäftsjahr 2024 nach schwierigem Jahr 2023 24.04.2024 / 07:05 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. SURTECO GROUP SE: Guter Start in das Geschäftsjahr 2024 nach schwierigem Jahr 2023 Gewinn je Aktie liegt in 2023 bei -0,79 € nach 1,63 € im Vorjahr Umsatz 2024 soll bei 860 bis 910 Mio. € liegen. EBITDA adjusted wird zwischen 85 und 105 Mio. € erwartet. Guter Start in das Geschäftsjahr 2024 mit einem Plus von 44 % im EBITD...
EQS-News: Evotec presents fiscal year 2023 results and announces prior...
EQS-News: Evotec SE / Key word(s): Annual Results Evotec presents fiscal year 2023 results and announces priority reset to focus on profitable growth 24.04.2024 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcement. FINANCIAL RESULTS FOR 2023 FULLY MET UPDATED GUIDANCE PRIORITY RESET TO PROFITABLE GROWTH: SIZE & FOOTPRINT ADJUSTMENTS TO DRIVE EXPECTED ANNUALISED EBITDA IMPROVEMENT GREATER THAN € 40 M EVOTEC’S REPORTING STRUCTURE WILL CHANGE TO BUSINESS SEGMENTS “SHARED R&D” AND “JUST – EVOTEC BIOLOGICS” STARTING Q1 2024 Hamburg, Germany,...
KALRAY DEVIENT MEMBRE DU PROGRAMME « ARM TOTAL DESIGN », RENFORÇANT SA...
GRENOBLE, France--(BUSINESS WIRE)-- Kalray (Euronext Growth Paris : ALKAL), leader dans les technologies matérielles et logicielles dédiées à la gestion et au traitement intensif des données du Cloud au Edge, annonce devenir membre du programme Arm Total Design de Arm. En travaillant plus étroitement avec les leaders de l'industrie qui exploitent les solutions CSS d’Arm (Compute Sub-System Solution), Kalray va permettre à davantage d'entreprises d’intégrer plus facilement sa technologie unique d'accélération de l'IA et du traitement des données. En outre, Kalray aidera les partenaires de l'éco...
Kalray Joins Arm Total Design, Extending Collaboration With Arm on Acc...
GRENOBLE, France--(BUSINESS WIRE)-- Kalray (Euronext Growth Paris: ALKAL), a leading provider of hardware and software solutions to accelerate data intensive workflows from Cloud to Edge, announced that it has extended its collaboration with Arm by joining Arm Total Design. Through a deeper connection to industry leaders who are leveraging Arm® Neoverse™ Compute Subsystems (CSS), Kalray can help more companies integrate its unique AI and data acceleration technology and help Arm ecosystem partners commercialize AI-based solutions in a fraction of the time and cost usually needed. Arm Total D...
- ABGSC Metals & Mining Research
- Adrian Gilani
Elliptic Labs Shipping Its AI Software Platform on Lenovo’s Newest Thi...
OSLO, Norway--(BUSINESS WIRE)-- (OSE:), a global AI software company and the world leader in AI Virtual Smart Sensors™, is now shipping its 100% software-only AI Virtual Human Presence Sensor on four select models of latest generation ThinkPad P Series workstation laptops — ThinkPad P1 Gen 7, P16v i Gen 2, P16s i Gen 3, and P14s i Gen 5. Elliptic Labs’ partner sits at these laptops’ core with its latest generation . Elliptic Labs announced the contract preceding this launch . Elliptic Labs’ AI Virtual Smart Sensor Platform™ leverages the company’s ultrasound, AI, and sensor fusion experti...
Galderma Delivers a Strong Start to the Year With Record Net Sales of ...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1 billion USD mark for the first three months in a year Net sales growth for the first quarter of 2024 was 12.4% year-on-year on a constant currency basis1, primarily driven by volume Broad-based growth across all product categories, with constant currency year-on-year growth of 19.3% for Injectable Aesthetics...
CARMAT annonce ses résultats annuels 2023 et fait un point sur ses ava...
PARIS--(BUSINESS WIRE)-- Regulatory News: CARMAT (FR0010907956, ALCAR, éligible PEA-PME), concepteur et développeur du cœur artificiel total le plus avancé au monde (la « Société » ou « CARMAT »), visant à offrir une alternative thérapeutique aux malades souffrant d’insuffisance cardiaque biventriculaire avancée, annonce aujourd’hui ses résultats annuels pour l’exercice clos au 31 décembre 2023 et fait un point sur ses avancées et perspectives 2024. Les comptes annuels ont été arrêtés par le conseil d’administration le 22 avril 2024, sur la base du principe de continuité d’exploitation. La...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results an...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically sig...
First quarter 2024 financial information: Good start to the year
First quarter 2024 financial information: Good start to the year Good start to the year _PRESS RELEASE_ First quarter 2024 standard sales of €1,692 million, up +2.8% organically year-on-year and up +4.7% excluding Other activitiesElectrification businesses up +6.7% organically, reflecting double digit growth in Generation & Transmission segment and an acceleration in electrification trends globally Record adjusted backlog for Generation & Transmission, mainly subsea-driven, at €6.7 billion, up +10.2% compared to December 2023Electrification Pure Player profile further strengthened ...
Information financière du premier trimestre 2024: Bon début d'année
Information financière du premier trimestre 2024: Bon début d'année Bon début d’année 2024 _COMMUNIQUÉ DE PRESSE_ Chiffre d’affaires standard de 1 692 millions d’euros au premier trimestre 2024, en croissance organique de +2,8 % par rapport à la même période de 2023 et de +4,7 % hors Autres activitésCroissance organique de +6,7 % des activités d'Electrification, reflétant une croissance à deux chiffres de l’activité Production d’énergie & Transmission et une accélération globale des tendances dans l'électrification Carnet de commandes ajusté record de 6,7 milliard...
BioSenic postpones its annual general meeting of the shareholders and ...
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going...
BioSenic reporte son assemblée générale annuelle des actionnaires et f...
BioSenic reporte son assemblée générale annuelle des actionnaires et fournit des chiffres financiers temporaires non-audités pour 2023 COMMUNIQUE DE PRESSE – INFORMATION PRIVILIGIEE Compte tenu du plan de restructuration annoncé le 11 avril 2024, BioSenic a décidé de reporter la publication de son rapport annuel 2023 ainsi que son assemblée générale annuelle des actionnaires, afin que le Tribunal de l'entreprise de Nivelles puisse prendre une décision avant l'accomplissement des formalités annuelles. La société estime que ce report est préférable pour s'assurer que les états financiers pe...
Reminder: Unifiedpost Group Strategy Update Presentation on 30 April 2...
Reminder: Unifiedpost Group Strategy Update Presentation on 30 April 2024 La Hulpe, Belgium – 24 April 2024, 7:00 a.m. CET – Unifiedpost Group SA (Euronext Brussels: UPG) (“Unifiedpost”), a leader in cloud-based business process solutions, will present an overview of its mid-term strategy on Tuesday, 30 April 2024.The event will take place from 2:00pm to 4:00pm CET on Tuesday, 30 April 2024. The presenting team will be Hans Leybaert, CEO, Koen De Brabander, CFO, and some of the group’s business leaders. The agenda for the day is as follows: Introductions Key objectives Business updat...
Wereldhave Trading update Q1 2024
Wereldhave Trading update Q1 2024 Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 202...
Melexis Q1 2024 results – First quarter sales of 241.8 million EUR
Melexis Q1 2024 results – First quarter sales of 241.8 million EUR Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium - April 24th, 2024, 07.00 hrs CET Dear, Please find herewith the link to our most recent press release: Attachment
Melexis Q1 2024 résultats – Chiffre d'affaires de 241.8 millions d'eur...
Melexis Q1 2024 résultats – Chiffre d'affaires de 241.8 millions d'euros au premier trimestre Information réglementée Déclaration intermédiaire par le Conseil d'administrationYpres, Belgique - le 24 avril 2024, 07.00 H. CET Veuillez trouver ici le lien vers notre dernier communiqué de presse: Pièce jointe
TGS Q1 2024 Presentation and Webcast
TGS Q1 2024 Presentation and Webcast OSLO, Norway (24 April 2024) - TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online. Access and registration for online attendees are available by copying and pasting this link into your browser: The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. For m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.